Adenine arabinoside is a purine nucleoside in which adenine is attached to arabinofuranose via a beta-N9-glycosidic bond. It has a role as a nucleoside antibiotic, an antineoplastic agent and a bacterial metabolite. It is a purine nucleoside and a beta-D-arabinoside. It is functionally related to an adenine.
Science-backed PDE/ADE, OEL & OEB derivation by certified toxicologists with ex-agency experts -
Vidarabine
Drug Overview
What is Vidarabine?
To derive PDE/ADE, OEL, and OEB values, Masuu Global follows a scientifically justified, risk-based toxicological assessment approach in accordance with internationally recognized guidelines and industry best practices that are widely accepted by regulatory authorities, including European Medicines Agency (EMA), Pharmaceutical Inspection Co-operation Scheme (PIC/S), and Agência Nacional de Vigilância Sanitária (ANVISA).
Request Your Assessment
Add this compound to your inquiry list and our team will follow up with full documentation, pricing, and licensing terms.
View Inquiry List →Full OEL derivation · ADE/PDE value · Control band assignment · All cited references · EMA / ICH Q9 compliance
Regulatory Framework
Assessment Methodology
Masuu Global follows a scientifically justified, risk-based toxicological approach aligned with internationally recognized guidelines accepted by EMA, PIC/S, and ANVISA.
EMA – Guideline on Setting Health-Based Exposure Limits (HBELs)
Provides the framework for establishing scientifically justified PDE/ADE values for use in shared manufacturing facilities.
PIC/S – Shared Facilities and Contamination Control Guidance
Supports the application of HBEL-based approaches for cross-contamination prevention and cleaning validation.
ICH Q9 – Quality Risk Management
Provides a structured methodology for risk identification, assessment, control, communication, and review.
ICH M7 – Assessment and Control of DNA-Reactive (Mutagenic) Impurities (where applicable)
Applied for compounds with potential mutagenic or genotoxic concerns.
Risk-Based Toxicological Assessment
Comprehensive evaluation of available toxicological and pharmacological data, including NOAEL, LOAEL, BMDL, pharmacological potency, carcinogenicity, reproductive and developmental toxicity, sensitization potential, and target organ toxicity.
Weight-of-Evidence (WoE) Approach
Integration and critical review of all relevant data sources, including non-clinical studies, clinical studies, human exposure data, pharmacological information, post-marketing safety data, and structure–activity relationship (SAR/QSAR) assessments.
How We Work
Report Preparation Process
Every assessment moves through a rigorous five-stage workflow — from data gathering to regulatory-ready delivery.
Comprehensive Data Review
Assessment of pharmacology, toxicology, clinical data, literature, and available regulatory information.
Scientific Evaluation
Identification of critical endpoints and selection of appropriate exposure limits.
PDE / HBEL Derivation
Transparent and scientifically justified calculations aligned with global toxicological principles.
Ex-Agency Expert Review (Our Differentiator)
Reports are reviewed with an ex-agency perspective, bringing regulatory expectations, inspection readiness, and practical implementation into every assessment.
Final Report Delivery
Regulatory-ready reports with scientific rationale, calculations, and clear recommendations by certified toxicologists (ERT, UKRT and DABT).
Ex-Agency Advantage
Why Masuu Global?
Our ex-agency toxicologists bring a practical regulatory perspective that transforms how assessments are built, reviewed, and defended.
Regulatory expectation–driven assessments aligned with how authorities actually evaluate submissions.
Inspection-ready reports — scientifically defensible and audit-prepared from day one.
Faster review cycles with direct decision support from certified toxicologists (ERT, UKRT, DABT).
Practical implementation recommendations that translate science into actionable contamination control.
Reduced internal effort — offload complex assessments without sacrificing quality or defensibility.
Global reach across PDE/ADE, HBEL, OEL, OEB, cleaning validation, and impurity assessments.
Ready to request your assessment?
Add this compound to your inquiry list, or browse our full database of 3,000+ molecules.
Frequently Asked Questions
Vidarabine is a chemical substance that may be handled in pharmaceutical and chemical manufacturing. The precise toxicological profile and occupational exposure considerations should be established from reliable substance-specific evidence rather than inferred from the name alone. Reviewing the available data and intended handling conditions can support a documented assessment of worker protection and potential cross-contamination risk.
A PDE or ADE sets a health-based limit on daily exposure to Vidarabine from residual carryover. Manufacturers use it in cross-contamination risk assessments and cleaning validation when the compound is processed in shared equipment or facilities. Whether a report is required depends on how it is used and on applicable regulatory expectations.
The assessment of Vidarabine may consider relevant repeat-dose toxicity, genotoxicity, reproductive and developmental toxicity, carcinogenicity, pharmacology, and other evidence where available. The data selected should be relevant to the substance and the intended assessment. The critical effect and point of departure should be supported by a documented scientific rationale, with limitations and uncertainties explained transparently.
For Vidarabine, pharmacological information and toxicological findings should be considered together when they are relevant to the intended assessment. The evaluator should distinguish therapeutic effects from adverse effects, consider the quality of the supporting studies, and identify the critical endpoint for the exposure assessment. The final rationale should explain how the selected evidence supports the conclusion and where uncertainty remains.
Potential carryover of Vidarabine is evaluated by considering the health-based limit, the manufacturing and cleaning process, shared equipment, residue pathways, and the analytical methods used to detect residues. The assessment should account for the actual use scenario and applicable quality requirements. A PDE can inform the health-based component of the evaluation, but final controls and acceptance criteria require a broader, documented risk assessment.
An OEL is derived by reviewing the toxicological and occupational health evidence, identifying the critical effect, and applying a recognized assessment methodology. The final value should come with a documented rationale, clearly stated units, and the exposure duration it applies to, so it can be used confidently in workplace risk assessment.
An OEB places Vidarabine in a hazard category using a defined banding framework and the available toxicological evidence. Criteria and numerical ranges differ between frameworks, so the report should identify the system used. The band then guides the level of containment and handling controls suited to the compound.
The assessment for Vidarabine should be reconsidered when material new toxicological information becomes available, the substance’s use or exposure circumstances change, or relevant regulatory guidance is updated. A review may also be appropriate if the manufacturing process, route of exposure, or risk-management assumptions change. Documenting the reason for review and the evidence considered helps maintain a transparent and current risk assessment.
An occupational exposure band for Vidarabine is generally a hazard-management category assigned using a defined banding framework, whereas an OEL is a numerical occupational exposure limit derived through an appropriate assessment methodology. An OEB may help guide containment and handling decisions, but it should not be represented as a numerical OEL. The report should identify the framework used and explain the scope and limitations of the band.
For Vidarabine, a PDE generally addresses an acceptable daily exposure in contexts such as residual carryover into another medicinal product, while an OEL addresses exposure in the workplace, commonly by inhalation over a specified period. They serve different risk-management purposes and are not interchangeable by default. The report should define the endpoint, route, units, assumptions, and intended application of each value.
Masuu Global follows a scientifically justified, risk-based approach aligned with internationally recognized guidance accepted by regulators, including the EMA guideline on health-based exposure limits, PIC/S guidance on shared facilities and contamination control, ICH Q9 quality risk management, and ICH M7 where applicable.
Use the Request Your Assessment option on this page and add Vidarabine to your inquiry list. The Masuu Global team will follow up with full documentation, pricing, and licensing terms. Mention your intended use and market so the scope of the report can be confirmed.
